Category: misconduct investigations

“We are living in hell:” Authors retract 2nd paper due to missing raw data

ijcA 2006 paper investigating the effects of docosahexaenoic acid (DHA) and celecoxib on prostate cancer cells has been retracted because it appears to contain panels that were duplicated, and the authors could not provide the raw data to show otherwise.

This is the second paper the authors have lost because they couldn’t furnish the original data to defend their work against allegations of image manipulation. The reason: the Institute for Cancer Prevention in New York, where the authors did the work, shut its doors abruptly in 2004, co-author Bhagavathi A. Narayanan told us. (The institute closed thanks to $5.7 million in grant that was misspent, the New York Post reported at the time.)

Recently, some of Narayanan’s papers have been questioned on PubPeer; her work has been the subject of an investigation at New York University, where Narayanan is now based.

Narayanan told us that the criticism of their work has deeply affected her and her co-authors:

Continue reading “We are living in hell:” Authors retract 2nd paper due to missing raw data

Former accounting prof adds his 33rd retraction

James Hunton
James Hunton

Former accounting professor James Hunton has added a 33rd retraction to his total, solidifying his position at #10 on our leaderboard.

Hunton’s official total is 33.5, since one journal retracted only one section of a paper, making it a “partial” retraction. Most of those retractions came last year, the fallout from an investigation at Bentley University which concluded that the accounting researcher had committed misconduct. Hunton resigned from the university in 2012 after his first retraction, citing family matters.

After the Bentley University investigation, the journal Contemporary Accounting Research conducted its own review of the paper, and found “no credible evidence exists to support the validity of the data in the study,” according to the retraction note for “Decision Aid Reliance: A Longitudinal Field Study Involving Professional Buy-Side Financial Analysts.”

Here’s the entire retraction note:

Continue reading Former accounting prof adds his 33rd retraction

Macchiarini may be dismissed from Karolinska; dean of research resigns

Paolo Macchiarini
Paolo Macchiarini

There’s more news to report on the story of surgeon Paolo Macchiarini, who’s been dogged by allegations of misconduct.

After the Karolinska Institutet (KI) announced it would not extend his contract and that he needed to “phase out” his research by November, it has now announced it may dismiss him.

In addition, Hans-Gustaf Ljunggren, KI’s Dean of Research, has resigned.

Here’s the statement we received from a KI spokesperson:

Continue reading Macchiarini may be dismissed from Karolinska; dean of research resigns

Journal retracts 7 papers by MD Anderson cancer researcher long under investigation

aggarwal
Bharat Aggarwal

An MD Anderson Cancer Center researcher who has been under investigation by the institution for at least several years has had seven papers retracted from a single journal.

Bharat Aggarwal told us in 2012 that MD Anderson was investigating his work, but in 2013 threatened to sue us for reporting on the case. Aggarwal is no longer listed in the MD Anderson directory, and an email to him there bounced.

This week, Biochemical Pharmacology retracted seven studies of which he is the only common author, noting the “data integrity has become questionable.” The papers have been cited a total of more than 500 times, according to Thomson Scientific’s Web of Knowledge; one has been designated as “highly cited.” Here are the seven retractions: Continue reading Journal retracts 7 papers by MD Anderson cancer researcher long under investigation

Sanction for Toronto researchers upheld despite court challenge

Shereen Ezzat
Sylvia Asa
Sylvia Asa

A Toronto hospital network is keeping two researchers’ labs closed even after an Ontario court quashed part of a misconduct finding by the institution.

Some background: After the University Health Network found evidence of falsified data, Sylvia Asa stepped down as Program Medical Director of the Laboratory Medicine Program, the largest hospital diagnostic laboratory in Canada. Due to the investigation, UHN suspended the labs of Asa and her husband Shereen Ezzat. In response, Asa and Ezzat asked an Ontario court to quash the misconduct findings; last month, the court overturned two out of three findings, and asked UHN to reconsider its sanction against the pair.

According to the Toronto Star, on February 4th the UHN notified the researchers that the sanction against them would be upheld, and it would not reopen the researchers’ labs.

The Star spoke to the researcher’s lawyer, Brian Moher who  Continue reading Sanction for Toronto researchers upheld despite court challenge

8th retraction appears for researcher who faked patient records

S00219150An 8th paper has been retracted for Anna Ahimastos, a heart researcher who faked patient records.

It’s the last in a chain of retractions that were the result of an investigation by her former workplace, Baker IDI Heart & Diabetes Institute in Australia. As with the others, she did not agree to the retraction.

The investigation found fabricated patients records in some papers; in other papers, such as the newly retracted 2010 study in Atherosclerosis, the original data source could not be verified.  The latest retraction — “A role for plasma transforming growth factor-β and matrix metalloproteinases in aortic aneurysm surveillance in Marfan syndrome?” — followed up on a previous clinical trial, examining how a blood pressure drug might help patients with a life-threatening genetic disorder.

That previous trial — which also included 17 patients with Marfan syndrome treated with either placebo or perindopril — has been retracted from JAMA; the New England Journal of Medicine has also retracted a related letter.

The latest retraction note conveys similar information to the other perindopril/Marfan syndrome retractions: Continue reading 8th retraction appears for researcher who faked patient records

Karolinska vice-chancellor resigns following criticism of Macchiarini investigation

Anders Hamsten
Anders Hamsten

Anders Hamsten announced he would be resigning as vice-chancellor from Karolinska Institutet (KI) in the early hours of Saturday, February 13.

In a press release we received at 12:16 a.m. local time in Stockholm, Hamsten issued the following statement:

Following the criticism on the so called Macchiarini affair at KI I conclude it will be hard for me to serve as Vice-Chancellor with the strength and credibility this university needs. I will therefore leave office.

Good thing we published a primer on the whole story a few hours ago. To recap: Continue reading Karolinska vice-chancellor resigns following criticism of Macchiarini investigation

Reading about embattled trachea surgeon Paolo Macchiarini? Here’s what you need to know

Paolo Macchiarini
Paolo Macchiarini

The media has been abuzz in the last few weeks with developments in the ongoing story about “super surgeon” Paolo Macchiarini. We’ve been covering the allegations against him for years (and invited him to publish a guest post on our site). Below, we present a timeline of recent events, to keep you abreast of what we know so far.

Macchiarini was famous long before accusations of misconduct arose, once-heralded for creating tracheas from cadavers and patients’ own stem cells. However, the glow of his success was diminished somewhat after some Karolinska Institutet (KI) surgeons filed a complaint in 2014 — alleging, for instance, Macchiarini had downplayed the risks of the procedure and not obtained proper consent. In response, KI issued an external review by Bengt Gerdin of Uppsala University.

Here’s what’s happened since: Continue reading Reading about embattled trachea surgeon Paolo Macchiarini? Here’s what you need to know

After 10 years, a whistleblower is vindicated. Here’s why he kept going.

Stefan Franzen
Stefan Franzen

Stefan Franzen doesn’t give up. Ten years ago, he began to suspect the data behind his colleagues’ research about using RNA to make palladium nanoparticles, a potentially valuable tool that ended up as a Science paper. Recently, the National Science Foundation (NSF) decided to cut off funding for Bruce Eaton and Dan Feldheim — currently at the University of Colorado at Boulder — and last week, Science retracted the paper. We talked to Franzen, based at North Carolina State University (NCSU), about his decade-long efforts, and how it feels to be finally vindicated.

Retraction Watch: How did you first begin to suspect the findings by Eaton and Feldheim?

Stefan Franzen: Starting in early 2005, I was collaborating with Drs. Eaton and Feldheim at NCSU, thanks to two joint grants from the W.M. Keck Foundation and NSF. During a group meeting in December of 2005, a graduate student showed electron microscopy data that were inconsistent with the assignment of the particles as palladium. Over time, we kept producing more data that called their findings into question; in April 2006, a postdoc showed that the hexagonal particles could be obtained without RNA. By then, I could see that there was a significant discrepancy between what was written in the articles and what was done and observed in the laboratory.

RW: How did you report your concerns?

Continue reading After 10 years, a whistleblower is vindicated. Here’s why he kept going.

Sparks fly in Finland over misconduct investigation

JEMResearchers in Finland are criticizing an investigation by VTT Technical Research Centre into one of its scientists.

The investigation followed allegations about the VTT’s plasma and serum metabolomics (QBIX) group, previously led by Matej Orešič (who is now based at the Steno Diabetes Center in Gentofte, Denmark) and Tuulia Hyötyläinen. Kai Simons, who conducted an earlier investigation of the group, and the Chancellor Emeritus at the University of Helsinki, have criticized VTT, saying it cut corners in its investigation.

VTT found no evidence of data tampering or falsification in a 2008 paper co-authored by Orešič in the Journal of Experimental Medicine, but said the paper — which has not been corrected or retracted — included some “exaggerated conclusions.” In turn, Orešič and Hyötyläinen filed a complaint for “an alleged violation of good scientific practice” by Simons during the initial investigation. Continue reading Sparks fly in Finland over misconduct investigation